X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2548) 2548
Book Review (329) 329
Publication (144) 144
Book Chapter (7) 7
Newsletter (4) 4
Conference Proceeding (3) 3
Magazine Article (3) 3
Newspaper Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2268) 2268
humans (1863) 1863
male (1245) 1245
female (1120) 1120
benzoates - therapeutic use (969) 969
benzoates - adverse effects (858) 858
adult (723) 723
middle aged (685) 685
animals (658) 658
benzoates - pharmacology (492) 492
benzoates - administration & dosage (489) 489
aged (471) 471
pharmacology & pharmacy (376) 376
treatment outcome (337) 337
benzimidazoles - therapeutic use (332) 332
telmisartan (302) 302
adolescent (279) 279
hypertension - drug therapy (276) 276
hematology (267) 267
abridged index medicus (244) 244
rats (236) 236
triazoles - therapeutic use (228) 228
child (227) 227
hypertension (217) 217
iron chelating agents - therapeutic use (212) 212
benzimidazoles - adverse effects (195) 195
analysis (193) 193
blood pressure - drug effects (191) 191
drug therapy, combination (191) 191
angiotensin ii type 1 receptor blockers - therapeutic use (190) 190
double-blind method (182) 182
dose-response relationship, drug (181) 181
deferasirox (177) 177
efficacy (175) 175
benzimidazoles - administration & dosage (174) 174
mice (174) 174
triazoles - adverse effects (174) 174
iron overload - drug therapy (173) 173
pyrazoles - therapeutic use (172) 172
time factors (172) 172
hydrazines - therapeutic use (169) 169
benzoic acid (166) 166
young adult (166) 166
iron chelating agents - adverse effects (162) 162
sodium benzoate (154) 154
administration, oral (147) 147
drug therapy (146) 146
benzimidazoles - pharmacology (140) 140
benzoates - pharmacokinetics (140) 140
antihypertensive agents - therapeutic use (139) 139
safety (139) 139
child, preschool (136) 136
care and treatment (135) 135
toxicology (135) 135
medicine & public health (134) 134
angiotensin-converting enzyme inhibitors - therapeutic use (131) 131
double-blind (131) 131
oncology (131) 131
benzoates - chemistry (128) 128
research (126) 126
prospective studies (123) 123
health aspects (122) 122
receptors, thrombopoietin - agonists (121) 121
therapy (120) 120
pyrazoles - adverse effects (119) 119
aged, 80 and over (118) 118
eltrombopag (118) 118
management (118) 118
hydrazines - adverse effects (117) 117
medicine, general & internal (117) 117
triazoles - administration & dosage (116) 116
purpura, thrombocytopenic, idiopathic - drug therapy (115) 115
iron overload - etiology (112) 112
risk factors (112) 112
peripheral vascular disease (111) 111
benzoates (110) 110
drug combinations (110) 110
iron overload (109) 109
iron chelating agents - administration & dosage (107) 107
deferoxamine (106) 106
internal medicine (102) 102
antihypertensive agents - adverse effects (101) 101
angiotensin-converting enzyme inhibitors - adverse effects (97) 97
biochemistry & molecular biology (94) 94
pediatrics (94) 94
angiotensin ii type 1 receptor blockers - adverse effects (93) 93
pharmacokinetics (92) 92
blood-pressure (90) 90
thrombocytopenia (90) 90
beta-thalassemia (88) 88
antihypertensive agents - administration & dosage (85) 85
oxidative stress (85) 85
ferritins - blood (84) 84
hypertension - physiopathology (84) 84
clinical trials as topic (83) 83
retrospective studies (83) 83
angiotensin ii type 1 receptor blockers - pharmacology (81) 81
blood pressure (81) 81
environmental sciences (80) 80
metabolism (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2373) 2373
German (63) 63
French (40) 40
Japanese (27) 27
Spanish (17) 17
Russian (15) 15
Italian (7) 7
Polish (4) 4
Swedish (4) 4
Chinese (3) 3
Norwegian (3) 3
Danish (2) 2
Dutch (2) 2
Hungarian (1) 1
Portuguese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Advanced Healthcare Materials, ISSN 2192-2640, 10/2017, Volume 6, Issue 20, pp. 1700313 - n/a
The pharmacological manipulation of liver X receptors (LXRs) has been an attractive therapeutic strategy for atherosclerosis treatment as they control reverse... 
atherosclerosis | targeted drug delivery | nanoparticles | liver X receptor (LXR) | GW3965 | PEGYLATED LIPOSOMAL DOXORUBICIN | MATERIALS SCIENCE, BIOMATERIALS | CHOLESTEROL | DRUG-DELIVERY | ENGINEERING, BIOMEDICAL | RESOLUTION | CARDIOTOXICITY | NANOSCIENCE & NANOTECHNOLOGY | CELLULAR UPTAKE | INFLAMMATION | GENE-EXPRESSION | POLYMER HYBRID NANOPARTICLES | Liver - pathology | Benzoates - therapeutic use | Nanoparticles - chemistry | Benzoates - chemistry | Cholesterol - blood | Polyethylene Glycols - chemistry | Collagen Type IV - chemistry | Drug Carriers - chemistry | Liver - drug effects | Liver X Receptors - agonists | Nanoparticles - metabolism | Receptors, LDL - deficiency | Nanomedicine | Disease Models, Animal | Collagen Type IV - metabolism | Receptors, LDL - genetics | Atherosclerosis - pathology | Atherosclerosis - drug therapy | Liver - metabolism | Mice, Inbred C57BL | Cells, Cultured | Macrophages - cytology | Atherosclerosis - metabolism | Mice, Knockout | Benzylamines - chemistry | Macrophages - metabolism | Animals | Lipid Metabolism - drug effects | Triglycerides - blood | Benzoates - pharmacology | Macrophages - drug effects | Mice | Benzylamines - pharmacology | Benzylamines - therapeutic use | Drugs | Complications and side effects | Drug delivery systems | Liver | Atherosclerosis | Physiological aspects | Polyols | Vehicles | Encapsulation | Polyethylenes | Lipids | Inflammatory response | Biosynthesis | Macrophages | Nanoparticles | Receptors | Polyethylene glycol | Rodents | liver X receptors | Lipoprotein (low density) receptors | Collagen (type IV) | Lipid metabolism | Lesions | Polyethylene | Hyperlipidemia | Pharmacology | Inflammation | Metabolism | Cholesterol | Arteriosclerosis | Index Medicus
Journal Article
Obesity, ISSN 1930-7381, 05/2013, Volume 21, Issue 5, pp. 985 - 992
Objective: Tesofensine is a novel triple monoamine reuptake inhibitor which is in development for the treatment of obesity. Preclinical and clinical data... 
MONOAMINE REUPTAKE INHIBITOR | NUTRITION & DIETETICS | METABOLISM | INDUCED OBESE RAT | FOOD-INTAKE | IN-VIVO | OVERWEIGHT | ENDOCRINOLOGY & METABOLISM | WEIGHT-LOSS | METOPROLOL | HYPERTENSIVE-RATS | SIBUTRAMINE | Antihypertensive Agents - pharmacology | Appetite Depressants - adverse effects | Benzoates - therapeutic use | Metoprolol - pharmacology | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Sympathomimetics - pharmacology | Anti-Obesity Agents - adverse effects | Male | Appetite Depressants - therapeutic use | Angiotensin II Type 1 Receptor Blockers - pharmacology | Anti-Obesity Agents - therapeutic use | Dose-Response Relationship, Drug | Heart Rate - drug effects | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Blood Pressure - drug effects | Benzimidazoles - therapeutic use | Sympathomimetics - adverse effects | Sympathomimetics - therapeutic use | Cardiovascular Diseases - etiology | Appetite Depressants - pharmacology | Appetite - drug effects | Metoprolol - therapeutic use | Energy Intake - drug effects | Antihypertensive Agents - therapeutic use | Rats, Sprague-Dawley | Feeding Behavior - drug effects | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Obesity - prevention & control | Benzoates - pharmacology | Benzimidazoles - pharmacology | Anti-Obesity Agents - pharmacology | Obesity | Automation | Statistical analysis | Dopamine | Nuclear magnetic resonance--NMR | Telemetry | Abdomen | Heart rate | Weight control | Rodents | Monitoring systems | Software | Drug dosages | Food | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
This large trial compared the angiotensin-receptor blocker telmisartan, the angiotensin-converting–enzyme inhibitor ramipril, and combination therapy with both... 
MEDICINE, GENERAL & INTERNAL | DESIGN | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | DOUBLE-BLIND | SYSTOLIC DYSFUNCTION | RANDOMIZED CLINICAL-TRIALS | CONGESTIVE-HEART-FAILURE | COMBINATION | CONVERTING-ENZYME-INHIBITORS | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | TICLOPIDINE | WARFARIN | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | REGIMENS | NON-INFERIORITY TRIALS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article